MaxCyte Q4 revenue $7.3M, down 16%; FY2025 revenue $33M; guides FY2026 $30-32M

MAXCYTE, INC.

Q4 2025 total revenue $7.3M (-16% YoY); Core revenue $6.8M (-22% YoY). Net loss $9.6M.
FY2025 total revenue $33.0M (-15% YoY); Core revenue $29.6M (-9% YoY). Net loss $44.6M.
Cash and investments $155.6M at Dec 31, 2025, vs $190.3M a year earlier.
FY2026 guidance: total revenue $30-32M ($25-27M core, $5M SPL); expects cash ≥$136M.
Ended 2025 with 32 SPLs, 13 clinical programs in clinic, and one commercial program.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAXCYTE, INC. reported full year 2026 results: revenue Expects 2026 revenue of $30-32 million. Guidance initiated.

Period: full year 2026
Revenue: Expects 2026 revenue of $30-32 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAXCYTE, INC. reported fourth quarter ended December 31, 2025 results: revenue total revenue of $7.3 million, net income net loss was $9.6 million.

Period: fourth quarter ended December 31, 2025
Revenue: total revenue of $7.3 million
Net income: net loss was $9.6 million
Result: reported results

Exact text from the filing

Total revenue for the fourth quarter of 2025 was $7.3 million, compared to $8.7 million in the fourth quarter of 2024, representing a decrease of 16%.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-033867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.